In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 275 of 375

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]	Technology appraisal guidance	18 November 2026
Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]	Technology appraisal guidance	10 February 2027
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke	Interventional procedures guidance	11 February 2027
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism	HealthTech guidance	TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
Pharmalgen for the treatment of bee and wasp venom allergy	Technology appraisal guidance	TBC
PillCam COLON 2 for investigation of the colon through direct visualisation	Diagnostics guidance	TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]	Technology appraisal guidance	TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	24 February 2027
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]	Technology appraisal guidance	17 September 2026
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]	Technology appraisal guidance	TBC
Polycystic ovary syndrome: assessment and management	NICE guideline	9 December 2026
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]	Technology appraisal guidance	TBC
Prostate cancer: diagnosis and management (update)	NICE guideline	TBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]	Technology appraisal guidance	TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]	Technology appraisal guidance	15 November 2017
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]	Technology appraisal guidance	8 July 2026
Renal cell carcinoma Pathways Pilot [ID6186]	Technology appraisal guidance	TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]	Technology appraisal guidance	TBC

Results per page

10
25
50
All